Silence Therapeutics PLC Capital Reinvestment Ratio
Silence Therapeutics PLC capital reinvestment ratio. Silence Therapeutics PLC (SLN) has a Capital Reinvestment Ratio of 0.00x as of June 2026, meaning it reinvests 0% of its operating cash flow ($1.49 Million) in capital expenditures ($3.00). See Silence Therapeutics PLC free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Silence Therapeutics PLC (2019–2021)
Capital reinvestment ratio of Silence Therapeutics PLC from 2019 to 2021. This chart tracks Silence Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods. See financial agility of Silence Therapeutics PLC to measure the company's free cash flow as a share of total liabilities.
Silence Therapeutics PLC Capital Reinvestment Ratio by Year (2019–2021)
Silence Therapeutics PLC capital reinvestment ratio by year from 2019 to 2021. For the full cash flow conversion analysis, see Silence Therapeutics PLC operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.20x | $9.19 Million | $1.80 Million | ▲ +3661.1% |
| 2019 | 0.01x | $1.73 Million | $9.00K | — |